Revolution Medicines
Tracked across 9 events · 938 articles · First seen Apr 15, 2026 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Revolution Medicines is the developer of daraxonrasib; the EMA phased review and FDA submission progress are key regulatory milestones that could lead to market approval and significant revenue.
Jul 07, 2026 · 7 articles
Business
BeOne Medicines and Revolution Medicines announced a multi-part collaboration on August 10, 2026. The deal includes a clinical collaboration to evaluate drug combinations combining select BeOne oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors…
Impact: Revolution Medicines expands its global reach through BeOne's regional infrastructure and receives milestone payments and royalties. It retains rights outside the licensed territories, including Japan and South Korea.
Aug 10, 2026 · 7 articles
Tech
Impact: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
May 29, 2026 · 74 articles
Regulatory
Impact: Revolution Medicines is the company that accused Erasca of patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, claiming improper comparisons to its own drug candidate RMC-6236. This action has negatively impacted Erasca.
May 19, 2026 · 323 articles
Regulatory
A securities class action lawsuit has been filed against Erasca (NASDAQ: ERAS) alleging that the company and certain executives made false and misleading statements regarding its lead oncology candidate, ERAS-0015, a pan-RAS molecular glue. The…
Impact: Revolution Medicines is the competitor whose patent and trade secret claims against Erasca triggered the stock drop. The allegations could strengthen its competitive position in the RAS-targeting space.
Jun 11, 2026 · 193 articles
Tech
Impact: Revolution Medicines>>> is developing daraxonrasib, a new drug targeting the RAS gene, which offers hope for patients to overcome resistance to standard treatments.
Jun 03, 2026 · 6 articles
Tech
The American Society for Radiation Oncology (ASTRO) published an updated clinical practice guideline for radiation therapy in pancreatic cancer, revising its 2019 recommendations. The guideline, authored by Chuong et al. and published in Practical Radiation…
Impact: The guideline highlights the potential of RAS inhibitors like daraxonrasib, which could expand the market for Revolution Medicines' drug and boost its stock.
Aug 13, 2026 · 6 articles
International
Impact: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.
May 18, 2026 · 316 articles
Business
Impact: Revolution Medicines is mentioned as a current board seat for Borellini; not directly affected by this event.
Jul 13, 2026 · 6 articles
90
Revolution Medicines funded studyASTRO Updates Pancreatic...
90
Revolution Medicines granted exclusive rights BeOne MedicinesBeOne and Revolution...
87
Revolution Medicines sent letter alleging infringement ErascaErasca Securities Fraud...
80
Erasca misrepresented preclinical data Revolution MedicinesErasca Securities Fraud...
80
BeOne Medicines signed collaboration Revolution MedicinesBeOne and Revolution...
ERGEN INTELLIGENCE
Track Revolution Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard